Scientific reports · 2026
Trajectories of antidepressant dispensing among privately insured transgender people in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beltran Theo Gabriel, Pence Brian W, Pate Virginia, Lund Jennifer L, Poteat Tonia C, Thomas Kathleen C, Ranapurwala Shabbar I, Matthews Derrick D, Hincapie-Castillo Juan M
Аннотация
Psychiatric medication utilization studies rarely identify transgender and gender diverse (TGD) people, masking TGD health inequities. This study assessed antidepressant prescription fill patterns and their predictors among a privately insured TGD sample with newly dispensed anti-depressants after a recent depression or anxiety diagnosis from Merative MarketScan commercial insurance claims from 2007 to 2021. We measured trajectories of antidepressants utilization over 6-months using group-based trajectory modeling (GBTM), then identified demographic and clinical predictors of medication utilization group membership. Among 2499 TGD people with depression or anxiety, we found three anti-depressant dispensing trajectory groups (short-term [21.1%], decreasing [32.3%], and long-term [46.6%]). TGD people with previous chronic co-morbidities or emergency department visits had an increased probability of shorter-term antidepressant dispensing compared to long-term dispensing. TGD people under the age of 25 and those with previous psychotherapy treatment were less likely to have shorter-term anti-depressant dispensing than those with older ages (25-64) and those without prior psychotherapy. This study provides real-world evidence of distinct anti-depressant dispensing patterns and predictive factors associated with shorter-term dispensing among TGD people. Policymakers, providers, and advocacy groups can utilize findings to inform tailored strategies to improve sustained antidepressant use among TGD people living with mental health conditions.